NOVN实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Jul 2023 @ 04:00):

Stats
今日成交量	6.93M
平均成交量	1.04M
市值	2.64M
EPS	$0 ( 2024-03-28 )
下一个收益日期	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.112
ATR14	$0.103 (183.93%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-27	Sanders Machelle	Sell	11 553	Common Stock
2023-06-06	John A. Donofrio	Buy	85 000	Restricted Stock Units
2023-06-06	Gay John M.	Buy	200 000	Restricted Stock Units
2023-06-07	Gay John M.	Buy	65 000	Common Stock
2023-06-06	Gay John M.	Buy	65 000	Restricted Stock Units

INSIDER POWER
60.87
Last 97 transactions
Buy: 4 746 863 \| Sell: 340 227

音量相关性

長: -0.41 (neutral)

短: -0.55 (weak negative)

Signal:(24.752) Neutral

Novan Inc 相关性

10 最正相关
ARKO	0.981
GLPG	0.962
SIRI	0.955
TTEC	0.953
CLOV	0.953
FOXF	0.95
HCDIP	0.943
WKSP	0.943
LPSN	0.942
SHEN	0.942

10 最负相关
VITL	-0.963
AEYE	-0.952
JAN	-0.945
TRMR	-0.943
ROOT	-0.942
PPC	-0.939
THRN	-0.938
CPTA	-0.936
VCTR	-0.936
RZLT	-0.935

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Novan Inc 相关性 - 货币/商品

-0.25
( neutral )

-0.78
( moderate negative )

0.00
( neutral )

-0.08
( neutral )

-0.49
( neutral )

0.85
( strong )

Novan Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$0

FY	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$0

FY	2022
营收:	$23.61M
毛利润:	$16.23M (68.74 %)
EPS:	$-0.890

FY	2021
营收:	$2.96M
毛利润:	$0.00 (0.00 %)
EPS:	$-1.740

Financial Reports:

No articles found.

Novan Inc

Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.